ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ACON vs BGLC // EV/EBITDA & P/E VALUATION

Aclarion Inc. (NASDAQ) VS. BioNexus Gene Lab Corp (NASDAQ) • 15-METRIC TALLY: ACON 4 — BGLC 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACON VS. BGLC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ACON BGLC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 9.00% 14.60% -5.60 BGLC /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -39.90% -20.10 BGLC /operating-margins <GO>
Net Profit Margin -60.00% -40.20% -19.80 BGLC /net-margins <GO>
Revenue Growth (YoY) 65.60% -21.90% +87.50 ACON /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 2.12 -1.92 BGLC /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 ACON /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 39.0 24.5 +14.50 ACON /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.7M $2.9M $2.8M ACON /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ACON REV BGLC REV ACON GROSS % BGLC GROSS % ACON FCF BGLC FCF
FY 2025 $75.7K $7.4M 9.0% 14.6% -$7.2M -$1.9M
FY 2024 $45.7K $9.5M -50.0% 13.6% -$5.3M -$2.3M
FY 2023 $75.4K $9.8M — — -$3.6M -$1.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACON // BETA —
BGLC // BETA —